Quick Specifications

Vial Size 10MG
BAC Water 2ML
Amount Per Unit 0.05MG PER UNIT
Recommended Dose 1MG TO 2MG (10 TO 20 UNITS)
Frequency 5 DAYS ON 2 OFF
Injection Type SUBCUTANEOUS
Timing Fasted Before Bed or Upon Waking

Research Overview

INCREASES ENDOGENOUS IGF-1 - MINIMAL EFFECTS ON GHRELIN - THERMOGENIC - INCREASE MUSCLE MASS

How It Works

GHRH Receptor Agonism

CJC-1295 is a growth hormone releasing hormone (GHRH) analogue that binds and activates GHRH receptors in the pituitary gland, stimulating growth hormone synthesis and secretion. It works upstream from GHRPs like ipamorelin, targeting a different receptor.

Extended Half-Life (DAC Version)

CJC-1295 With DAC (Drug Affinity Complex) bonds to albumin in the bloodstream, extending its half-life from minutes to approximately 7–8 days. This allows once-weekly dosing while maintaining consistent GHRH receptor stimulation.

Synergistic GHRH + GHRP Action

When combined with ipamorelin or other GHRPs, CJC-1295 activates both the GHRH and ghrelin receptor pathways simultaneously, producing synergistic GH release substantially greater than either peptide alone — a key reason this combination is among the most studied.

Commonly Studied With

These peptides are frequently researched alongside CJC1295 - No DAC: 10mg due to complementary mechanisms:

Research & Educational Purposes Only

CJC1295 - No DAC: 10mg information on this page is for research and educational purposes only. This content is not FDA-approved, does not constitute medical advice, and should not be used to guide personal health decisions. Consult a qualified healthcare professional before using any research compound.

Dose Calculator

Enter your target dose to calculate the volume to draw.

in mcg

Recommended dose: 1MG TO 2MG (10 TO 20 UNITS)